Amundi
CRSP icon

Amundi’s CRISPR Therapeutics CRSP Stock Holding History

Amundi’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,262
Closed -$393K – 2093
2026
Q1 		$393K Buy
+8,262
New +$436K ﹤0.01% 1639
2025
Q2 		– Sell
-9
Closed -$294 – 1786
2025
Q1 		$294 Hold
9
– – ﹤0.01% 2154
2024
Q4 		$372 Buy
+9
New +$425 ﹤0.01% 2125
2022
Q4 		– Sell
-39,268
Closed -$2.54M – 1923
2022
Q3 		$2.54M Buy
39,268
+36,001
+1,102% +$2.61M ﹤0.01% 1112
2022
Q2 		$268K Hold
3,267
– – ﹤0.01% 1331
2022
Q1 		$209K Sell
3,267
-276
-8% -$17.3K ﹤0.01% 1384
2021
Q4 		$235K Hold
3,543
– – ﹤0.01% 1476
2021
Q3 		$397K Hold
3,543
– – ﹤0.01% 1375
2021
Q2 		$574K Buy
+3,543
New +$431K ﹤0.01% 1265

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Amundi's CRSP Position: Q2 2026 in Review

Amundi sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 8,262 shares — an estimated $393K sold.

Amundi first reported a position in CRSP in Q2 2021 and held it in 9 quarters. The position peaked at $2.54M in Q3 2022. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Amundi reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Amundi sold 8,262 CRISPR Therapeutics shares in Q2 2026, an estimated $393K.
  • Amundi first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 9 quarters.
  • Amundi's CRISPR Therapeutics position peaked at $2.54M in Q3 2022.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.